Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENUMQ FINRA Deleted Symbol
Shares Cancelled - Bankruptcy
http://otce.finra.org/DailyList
Here we go!!!!!!!
I see 0,01.Nothing on the ask size
ENUM changed to ENUMQ, bankruptcy:
http://otce.finra.org/DLSymbolNameChanges
8k out, Chapter 11
On January 29, 2018, the Company and its wholly-owned subsidiaries, Enumeral Biomedical Corp. (“EBC”) and Enumeral Securities Corporation, filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code
$ENUM
Zacks Investment Research, Inc. resumes coverage for ENUMERAL BIOMEDICA with BUY recommendation.
BY Investars Analyst Actions - private
— 12:18 PM ET 01/19/2018
On January 19, 2018 Zacks Investment Research, Inc. resumed coverage for ENUMERAL BIOMEDICA with a BUY recommendation.
https://eresearch.fidelity.com/eresearch/evaluate/news/basicNewsStory.jhtml?symbols=ENUM&storyid=201801191218WSOD____ANACTN_P_225-175426_43119-20180119-54978213&provider=WSOD____&product=ANACTN_P
Haha. Man!!! I was just reading your messages and thinking, "what is this dude smoking this MLK day" haha. $.39 right about now will be awesome though
market is closed. gosh i'm an idiot lol
i think td ameritrade is just jacked up
the ask says .39 - earthquake coming?
Signal shows buy and stay long. Don't sell it, go long. https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ENUM
I am accumulating this for long term and playing VICT for short term.
We will see $0.03 in two months.
ENUM currently winding down its operations, disposing of its remaining assets, see recent 10Q
Stock Watch: ENUM Higher 42.86% Over The Last Month!
http://lenoxledger.com/stock-watch-enumeral-biomedical-enum-higher-42-86-over-the-last-month/
ENUM = $0.07 Undervalued! https://online.capitalcube.com/#!/stock/us/otc/enum
ENUM~~Corporate Overview
Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Our unique platform allows us to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases, giving us the potential to positively affect millions of patients who are underserved by current therapeutic alternatives.
The core technology behind our platform was developed at and licensed from the Massachusetts Institute of Technology, Harvard University, Whitehead Institute for Biomedical Research and Massachusetts General Hospital. Our human-driven immunoprofiling platform enables us to extensively interrogate the human immune microenvironment to identify and validate potential drug candidates.
Our platform enables us to study rare immune cells from human patients at high resolution and measure drug effects in a patient-specific, disease-specific manner. Harnessing The Power of Human™, our platform provides a basis for developing best-in-class product candidates from a fundamental understanding of how immunotherapies work in each patient. Our vision then is to use this human-derived knowledge to better predict which antibody drug candidates are most likely to be effective in a targeted group of patients, with the goals of reducing side effects and accelerating the drug discovery process. Our discoveries will not only be valuable for the development of therapeutic antibodies but also as potential diagnostic products.
Initially, we are building a pipeline of immunomodulators that target checkpoint proteins, which the body use to prevent runaway immune responses that can prove debilitating or even deadly. Our near term goals include preclinical testing for our internal pipeline programs in our human-driven platform, as well as in other preclinical models.
We are leveraging the breadth of our technology through strategic collaborations. To date, we have engaged in several proof-of-concept collaborations with several leading pharmaceutical companies. Through them, our technology has been validated in a commercial setting, and a number of applications have been demonstrated.
In July 2014, we raised $21.5 million through a private placement offering and began public trading on the OTC Markets (OTCQB) with the ticker ENUM.
ENUM~~~Share Information
ENUM is in a share class of common stock Float 106.9M
Shares Outstanding 128.4M
Institutions Holding Shares 1
% Held by Institutions 2.69%
ENUM~~NEW WEBSITE~~http://www.enumeral.com/
I don’t know if it was last week but 3m bid appeared around this level.
I moved to this from TFVR adding some. Horrible dilution.
This looks good. Very low float and no dilution. Lots room to up.
Here we go.nothing to 0,03
lol 4m bid watching l2 hoping mm get caught with their pants down like Tuesday
preparing for blast off. setting up nicely
Anyone else notice near eod CDEL post up at .004 absorb 400k+ then get on the ask at .004 with identical size
pretty sure the float is totally locked
The ask at 0,004 is fake
This stock will fly.nothing on the ask size.300.000 shares to 0,011 and then 0,39.Good luck
$ENUM was at .13 earlier last year.....with the Same Share Structure....WAY WAY undervalued in the .00's.........lol.......z
Could be insiders buying $ENUM....hence not much on IHub......et z
This one looks interesting.
Good share structure.
Wouldn't take very much to push
this one higher. IMO
mikewazowski
Wave of volume like yesterday mm will be scrambling
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1095
|
Created
|
08/13/14
|
Type
|
Free
|
Moderators |
Shares Outstanding | 51,591,710 | a/o Jul 31, 2014 |
Float | Not Available | |
Authorized Shares | 75,000,000 | a/o Jul 31, 2013 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |